Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial

Nina Schooler, Jonathan Rabinowitz, Michael Davidson, Robin Emsley, Philip D Harvey, Lili Kopala, Patrick D. McGorry, Ilse Van Hove, Marielle Eerdekens, Wim Swyzen, Goedele De Smedt

Research output: Contribution to journalArticle

287 Citations (Scopus)

Abstract

Objective: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment corner-stone during the first years of illness because active psychotic illness may affect lifetime outcomes. Thus, initial treatment of active symptoms and subsequent relapse prevention are central goals of pharmacotherapy. This study compared long-term effectiveness of risperidone versus haloperidol in first-episode psychosis patients. Method: First-episode psychosis patients (N=555, mean age=25.4 years) participated in a double-blind, randomized, controlled flexible-dose trial that compared risperidone (mean modal dose=3.3 mg) and haloperidol (mean modal dose= 2.9 mg). The median treatment length was 206 days (maximum=1,514). Results: Positive and Negative Syndrome Scale scores and Clinical Global Impression ratings improved significantly relative to baseline, with no significant differences between groups. Three-quarters of the patients achieved initial clinical improvement, defined as >20% reduction in total Positive and Negative Syndrome Scale score. However, among those who achieved clinical improvement, 42% of the risperidone group experienced a relapse compared with 55% of the haloperidol group. The median time to relapse was 466 days for risperidone-treated subjects and 205 days for those given haloperidol. These differences were statistically significant based on Kaplan-Meier survival analysis. Adverse effects distinguished the treatments: there were significantly more extrapyramidal signs and symptoms and adjunctive medication use in the haloperidol group and greater prolactin elevation in the risperidone group. There was less weight gain with haloperidol initially but no significant differences between groups at endpoint. Conclusions: Relatively low doses of antipsychotic drugs lead to significant symptom amelioration in the majority of first-episode psychosis patients. In the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol.

Original languageEnglish
Pages (from-to)947-953
Number of pages7
JournalAmerican Journal of Psychiatry
Volume162
Issue number5
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Risperidone
Haloperidol
Psychotic Disorders
Secondary Prevention
Recurrence
Therapeutics
Dyskinesias
Kaplan-Meier Estimate
Survival Analysis
Prolactin
Antipsychotic Agents
Signs and Symptoms
Weight Gain
Drug Therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., ... De Smedt, G. (2005). Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. American Journal of Psychiatry, 162(5), 947-953. https://doi.org/10.1176/appi.ajp.162.5.947

Risperidone and haloperidol in first-episode psychosis : A long-term randomized trial. / Schooler, Nina; Rabinowitz, Jonathan; Davidson, Michael; Emsley, Robin; Harvey, Philip D; Kopala, Lili; McGorry, Patrick D.; Van Hove, Ilse; Eerdekens, Marielle; Swyzen, Wim; De Smedt, Goedele.

In: American Journal of Psychiatry, Vol. 162, No. 5, 01.05.2005, p. 947-953.

Research output: Contribution to journalArticle

Schooler, N, Rabinowitz, J, Davidson, M, Emsley, R, Harvey, PD, Kopala, L, McGorry, PD, Van Hove, I, Eerdekens, M, Swyzen, W & De Smedt, G 2005, 'Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial', American Journal of Psychiatry, vol. 162, no. 5, pp. 947-953. https://doi.org/10.1176/appi.ajp.162.5.947
Schooler, Nina ; Rabinowitz, Jonathan ; Davidson, Michael ; Emsley, Robin ; Harvey, Philip D ; Kopala, Lili ; McGorry, Patrick D. ; Van Hove, Ilse ; Eerdekens, Marielle ; Swyzen, Wim ; De Smedt, Goedele. / Risperidone and haloperidol in first-episode psychosis : A long-term randomized trial. In: American Journal of Psychiatry. 2005 ; Vol. 162, No. 5. pp. 947-953.
@article{d08b1a9a7a004573bfc6cb478c34bf92,
title = "Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial",
abstract = "Objective: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment corner-stone during the first years of illness because active psychotic illness may affect lifetime outcomes. Thus, initial treatment of active symptoms and subsequent relapse prevention are central goals of pharmacotherapy. This study compared long-term effectiveness of risperidone versus haloperidol in first-episode psychosis patients. Method: First-episode psychosis patients (N=555, mean age=25.4 years) participated in a double-blind, randomized, controlled flexible-dose trial that compared risperidone (mean modal dose=3.3 mg) and haloperidol (mean modal dose= 2.9 mg). The median treatment length was 206 days (maximum=1,514). Results: Positive and Negative Syndrome Scale scores and Clinical Global Impression ratings improved significantly relative to baseline, with no significant differences between groups. Three-quarters of the patients achieved initial clinical improvement, defined as >20{\%} reduction in total Positive and Negative Syndrome Scale score. However, among those who achieved clinical improvement, 42{\%} of the risperidone group experienced a relapse compared with 55{\%} of the haloperidol group. The median time to relapse was 466 days for risperidone-treated subjects and 205 days for those given haloperidol. These differences were statistically significant based on Kaplan-Meier survival analysis. Adverse effects distinguished the treatments: there were significantly more extrapyramidal signs and symptoms and adjunctive medication use in the haloperidol group and greater prolactin elevation in the risperidone group. There was less weight gain with haloperidol initially but no significant differences between groups at endpoint. Conclusions: Relatively low doses of antipsychotic drugs lead to significant symptom amelioration in the majority of first-episode psychosis patients. In the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol.",
author = "Nina Schooler and Jonathan Rabinowitz and Michael Davidson and Robin Emsley and Harvey, {Philip D} and Lili Kopala and McGorry, {Patrick D.} and {Van Hove}, Ilse and Marielle Eerdekens and Wim Swyzen and {De Smedt}, Goedele",
year = "2005",
month = "5",
day = "1",
doi = "10.1176/appi.ajp.162.5.947",
language = "English",
volume = "162",
pages = "947--953",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "5",

}

TY - JOUR

T1 - Risperidone and haloperidol in first-episode psychosis

T2 - A long-term randomized trial

AU - Schooler, Nina

AU - Rabinowitz, Jonathan

AU - Davidson, Michael

AU - Emsley, Robin

AU - Harvey, Philip D

AU - Kopala, Lili

AU - McGorry, Patrick D.

AU - Van Hove, Ilse

AU - Eerdekens, Marielle

AU - Swyzen, Wim

AU - De Smedt, Goedele

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Objective: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment corner-stone during the first years of illness because active psychotic illness may affect lifetime outcomes. Thus, initial treatment of active symptoms and subsequent relapse prevention are central goals of pharmacotherapy. This study compared long-term effectiveness of risperidone versus haloperidol in first-episode psychosis patients. Method: First-episode psychosis patients (N=555, mean age=25.4 years) participated in a double-blind, randomized, controlled flexible-dose trial that compared risperidone (mean modal dose=3.3 mg) and haloperidol (mean modal dose= 2.9 mg). The median treatment length was 206 days (maximum=1,514). Results: Positive and Negative Syndrome Scale scores and Clinical Global Impression ratings improved significantly relative to baseline, with no significant differences between groups. Three-quarters of the patients achieved initial clinical improvement, defined as >20% reduction in total Positive and Negative Syndrome Scale score. However, among those who achieved clinical improvement, 42% of the risperidone group experienced a relapse compared with 55% of the haloperidol group. The median time to relapse was 466 days for risperidone-treated subjects and 205 days for those given haloperidol. These differences were statistically significant based on Kaplan-Meier survival analysis. Adverse effects distinguished the treatments: there were significantly more extrapyramidal signs and symptoms and adjunctive medication use in the haloperidol group and greater prolactin elevation in the risperidone group. There was less weight gain with haloperidol initially but no significant differences between groups at endpoint. Conclusions: Relatively low doses of antipsychotic drugs lead to significant symptom amelioration in the majority of first-episode psychosis patients. In the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol.

AB - Objective: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment corner-stone during the first years of illness because active psychotic illness may affect lifetime outcomes. Thus, initial treatment of active symptoms and subsequent relapse prevention are central goals of pharmacotherapy. This study compared long-term effectiveness of risperidone versus haloperidol in first-episode psychosis patients. Method: First-episode psychosis patients (N=555, mean age=25.4 years) participated in a double-blind, randomized, controlled flexible-dose trial that compared risperidone (mean modal dose=3.3 mg) and haloperidol (mean modal dose= 2.9 mg). The median treatment length was 206 days (maximum=1,514). Results: Positive and Negative Syndrome Scale scores and Clinical Global Impression ratings improved significantly relative to baseline, with no significant differences between groups. Three-quarters of the patients achieved initial clinical improvement, defined as >20% reduction in total Positive and Negative Syndrome Scale score. However, among those who achieved clinical improvement, 42% of the risperidone group experienced a relapse compared with 55% of the haloperidol group. The median time to relapse was 466 days for risperidone-treated subjects and 205 days for those given haloperidol. These differences were statistically significant based on Kaplan-Meier survival analysis. Adverse effects distinguished the treatments: there were significantly more extrapyramidal signs and symptoms and adjunctive medication use in the haloperidol group and greater prolactin elevation in the risperidone group. There was less weight gain with haloperidol initially but no significant differences between groups at endpoint. Conclusions: Relatively low doses of antipsychotic drugs lead to significant symptom amelioration in the majority of first-episode psychosis patients. In the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol.

UR - http://www.scopus.com/inward/record.url?scp=21044457943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044457943&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.162.5.947

DO - 10.1176/appi.ajp.162.5.947

M3 - Article

C2 - 15863797

AN - SCOPUS:21044457943

VL - 162

SP - 947

EP - 953

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 5

ER -